US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
CN100381437C
(zh)
|
2002-04-17 |
2008-04-16 |
赛特凯恩蒂克公司 |
化合物、组合物和方法
|
MXPA04011074A
(es)
|
2002-05-09 |
2005-06-08 |
Cytokinetics Inc |
Compuestos de pirimidinona, composiciones y metodos.
|
ES2282647T3
(es)
|
2002-06-14 |
2007-10-16 |
MERCK & CO., INC. |
Inhibidores de cinesina mitotica.
|
CA2487489C
(en)
|
2002-06-14 |
2010-11-23 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
US6949538B2
(en)
|
2002-07-17 |
2005-09-27 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
US20040048853A1
(en)
*
|
2002-08-21 |
2004-03-11 |
Gustave Bergnes |
Compounds, compositions, and methods
|
MXPA05009577A
(es)
*
|
2003-03-07 |
2005-12-12 |
Astrazeneca Ab |
Heterociclos fundidos novedosos y sus usos.
|
WO2006018628A1
(en)
*
|
2003-03-07 |
2006-02-23 |
Astrazeneca Ab |
Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
|
US7022850B2
(en)
|
2003-05-22 |
2006-04-04 |
Bristol-Myers Squibb Co. |
Bicyclicpyrimidones and their use to treat diseases
|
US7345046B2
(en)
*
|
2003-05-30 |
2008-03-18 |
Chiron Corporation |
Heteroaryl-fused pyrimidinyl compounds as anticancer agents
|
AR045342A1
(es)
*
|
2003-08-15 |
2005-10-26 |
Merck & Co Inc |
Inhibidores de quinesina mitotica
|
SI1664026T1
(sl)
*
|
2003-08-15 |
2009-04-30 |
Merck & Co Inc |
Inhibitorji mitotiäśnega kinezina
|
EP1656146A4
(de)
|
2003-08-15 |
2009-04-15 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
AU2004264533B2
(en)
|
2003-08-15 |
2009-01-22 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
WO2005046588A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
ES2311992T3
(es)
|
2004-05-21 |
2009-02-16 |
Novartis Vaccines And Diagnostics, Inc. |
Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
|
AU2005258135B2
(en)
|
2004-06-18 |
2011-09-22 |
Novartis Vaccines And Diagnostics Inc. |
N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
|
AU2005263969A1
(en)
*
|
2004-07-22 |
2006-01-26 |
Astrazeneca Ab |
Fused pyrimidones useful in the treatment and the prevention of cancer
|
US20080293744A1
(en)
*
|
2004-08-18 |
2008-11-27 |
Astrazeneca Ab |
Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer
|
US20060041128A1
(en)
*
|
2004-08-18 |
2006-02-23 |
Astrazeneca Ab |
Selected fused heterocyclics and uses thereof
|
EP1781673B1
(de)
*
|
2004-08-18 |
2009-10-21 |
AstraZeneca AB |
Ausgewählte kondensierte heterocyclen und deren anwendung
|
US7608723B2
(en)
|
2004-10-19 |
2009-10-27 |
Novartis Vaccines And Diagnostics, Inc. |
Indole and benzimidazole derivatives
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
MY153714A
(en)
|
2006-06-28 |
2015-03-13 |
Amgen Inc |
Glycine transporter-1 inhibitors
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
KR20090081020A
(ko)
|
2006-11-13 |
2009-07-27 |
노파르티스 아게 |
Ksp 억제제로서의 치환된 피라졸 및 트리아졸 화합물
|
CN101622247A
(zh)
|
2007-01-05 |
2010-01-06 |
诺瓦提斯公司 |
作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物
|
PL2336120T3
(pl)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
CA2685967A1
(en)
|
2007-05-21 |
2008-11-21 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EA201070611A1
(ru)
*
|
2007-11-13 |
2010-12-30 |
Айкос Корпорейшн |
Ингибиторы человеческой фосфатидилинозитол-3-киназы дельта
|
EP2070932A1
(de)
*
|
2007-12-13 |
2009-06-17 |
4Sc Ag |
Pyrazolotriazine
|
TWI404721B
(zh)
*
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基-雜環化合物
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
PE20121172A1
(es)
|
2009-10-14 |
2012-09-05 |
Merck Sharp & Dohme |
Piperidinas sustituidas con actividad en la hdm2
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2632472B1
(de)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
|
EP2455456A1
(de)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
IN2013MN02170A
(de)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2844261B1
(de)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
MX363243B
(es)
|
2012-11-28 |
2019-03-14 |
Merck Sharp & Dohme |
Composiciones para tratar cáncer y usos de dichas composiciones.
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
BR112016014830A2
(pt)
|
2013-12-23 |
2017-09-19 |
Bayer Pharma AG |
Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
JP6743015B2
(ja)
|
2014-12-15 |
2020-08-19 |
バイエル ファーマ アクチエンゲゼルシャフト |
Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類)
|
CN114917361A
(zh)
|
2015-06-22 |
2022-08-19 |
拜耳医药股份有限公司 |
具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc)
|
US11071788B2
(en)
|
2015-06-23 |
2021-07-27 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
|
CA2990394A1
(en)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
|
EP3919518A1
(de)
|
2016-06-15 |
2021-12-08 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate mit ksp-inhibitoren und anti-cd123-antikörpern
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3558388A1
(de)
|
2016-12-21 |
2019-10-30 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
|
EP3558387B1
(de)
|
2016-12-21 |
2021-10-20 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
MX2019012233A
(es)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anticuerpos anti-sirpa.
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CA3103327A1
(en)
|
2018-06-18 |
2019-12-26 |
Bayer Aktiengesellschaft |
Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
KR20220123229A
(ko)
|
2019-12-17 |
2022-09-06 |
머크 샤프 앤드 돔 엘엘씨 |
Prmt5 억제제
|